Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Net Income (Common)
Interpace Biosciences Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Net Income (Common)
-$1.6m
|
CAGR 3-Years
63%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
DaVita Inc
NYSE:DVA
|
Net Income (Common)
$691.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
34%
|
CAGR 10-Years
1%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Net Income (Common)
$843m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
CVS Health Corp
NYSE:CVS
|
Net Income (Common)
$8.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
Cigna Corp
NYSE:CI
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Net Income (Common)
$433.1m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
See Also
What is Interpace Biosciences Inc's Net Income (Common)?
Net Income (Common)
-1.6m
USD
Based on the financial report for Sep 30, 2023, Interpace Biosciences Inc's Net Income (Common) amounts to -1.6m USD.
What is Interpace Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
24%
Over the last year, the Net Income (Common) growth was 93%. The average annual Net Income (Common) growth rates for Interpace Biosciences Inc have been 63% over the past three years , 34% over the past five years , and 24% over the past ten years .